COVID-19 Vaccine Information
Beebe has a plan to support the vaccination efforts in our community. The roll-out of Phase 1B (persons 65+ and essential workers) depends on many factors, including federal allotment, and shipments to the state of Delaware.
Thank you for the privilege of being your healthcare partner. Please click on the buttons below to get the latest information on the COVID-19 vaccine.
Beebe's parking garage is undergoing a restoration project starting March 1 which will limit some parking there. Free valet service is available at our Main Entrance (west side of hospital). Learn more.
INFORMATION IN THIS DIGITAL RESOURCE
It is important – even once you are vaccinated - to continue to practice the three Ws:
Wash your hands, Watch your distance, and Wear a mask.
Watch the Latest Town Hall Videos
Get On A Vaccine Waiting List - For Those 65 & Older
NOTE: You must sign up for each Wait List individually. Signing up for one does not automatically mean you are on another. Also check your local pharmacy for their Wait List opportunities.
Beebe Healthcare is offering a Beebe COVID-19 Vaccine Wait List. This list is open to anyone age 65 or older who wants to be included in future communications and scheduling options to receive the vaccine through Beebe. Beebe has been receiving limited supplies from the state allotment. As supplies become available, we will be offering vaccines based on the state's phases. To be included on Beebe's wait list, click the button below.
Please note: By signing up for either wait list, you will receive an email. Please check SPAM folders regularly.
For more information or to call to get on Beebe's COVID-19 Wait List, call 302-645-3200.
The state of Delaware is also offering a wait list for future vaccination scheduling for those 65 and older. The state will be offering mass vaccination events throughout the state for residents. These events are by appointment only. To get on the list for an appointment based on the state's phases, click the button below.
If you or a loved one is 65 or older and would like to request a vaccine appointment, go to vaccinerequest.delaware.gov. If you do not have computer access, you can call 1-833-643-1715 for assistance.
Questions about the COVID-19 vaccines? Contact the Division of Public Health Vaccine Call Center at 1-833-643-1715. The call center is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, and from 10:00 a.m. to 4:00 p.m. on Saturday. Or email Vaccine@delaware.gov.
Other options for vaccination include:
- Your independent primary care provider (if they choose to provide vaccines)
- Public health clinics by the Division of Public Health
- Federally Qualified Health Centers
Learn about all the options on where you can be vaccinated: coronavirus.delaware.gov/vaccine/where-can-i-get-my-vaccine
Not everyone eligible for Phase 1B will be able to receive the vaccine right away due to limited supply. As soon as we receive supplies, we will get them into the arms of our community, following the Tier system directed by the state of Delaware.
When Can I Be Vaccinated?
In accordance with the CDC, the state of Delaware’s vaccine distribution plan is a phased approach with the goal of reducing death and severe illness.
Many Sussex Countians will be eligible to receive the vaccine during Phase 1B, which includes persons 65 and older, along with other essential workers.
- Phase 1A: Health care personnel, Emergency Medical Services agencies, and long-term care staff and residents received the vaccine first.
- Phase 1B: By the end of January 2021, those who are ages 65 and older, as well as those considered frontline essential workers including: police, fire, teachers, child care providers, food processing workers, correctional officers, and postal service, public transit and grocery workers will begin to be vaccinated.
- Remaining Phase 1: Starting by end of February people in the following categories are expected to be eligible to receive a vaccine:
- Persons aged 16-64 with high-risk medical conditions
- Persons living in high-risk group settings such as correctional facilities, homeless shelters, and group homes
- Other essential workers.
- Phase 2: Beginning in mid-late April, persons aged 50 – 64, persons 16 – 49 with moderate-risk medical conditions, other in group settings who did not receive vaccine in the earlier phases, and essential workers not able to work from home at all times, are likely to receive the vaccine.
- Phase 3: Persons aged 16-49 and essential workers not receiving the vaccine in Phase 2 are likely to receive the vaccine in mid-late May.
- Phase 4: By late May/early June, those who have not already received the vaccine will be able to access it through primary care providers, pharmacies, and health centers (for patients).
To understand how many vaccine doses are being delivered to Delaware and how the phases are organized, visit My Health Community.
What About the Second Dose?
When you should get your second dose: The CDC recently announced that you may have a second dose up to 42 days after your first dose and still be protected.
With that updated scientific guidance, the Division of Public Health informed vaccine partners to schedule second doses between 28 and 35 days after the first dose is administered if receiving the second dose is not feasible within the manufacturer recommended timeline. This policy enables the state to continue administering first doses to the vulnerable 65+ population at highest risk of hospitalization and death.
The CDC also said if you do not receive your second dose within 42 days that you do not need to restart the series over again.
However, you should not get the second dose before the recommended interval (21 days for Pfizer or 28 days for Moderna) and your first and second does must be from the same vaccine (for instance both Pfizer or both Moderna).
If you had your first dose through Beebe: We are keeping a tally that of those who have received the first at Beebe’s Vaccine clinic. As vaccine becomes available and you are eligible for the second dose, we will be reaching out to you for the option to receive your second dose via email within the recommended timeframe, according to the guidance from CDC and DPH. Beebe is striving to adhere to the manufacturer recommended timeline as supply allows.
If you got your first dose through the state of Delaware: If you received your first dose at a DMV drive-thru event, the State of Delaware will be contacting you to schedule your second dose. Go to the Frequently Asked Questions section for more information.
Additionally, the Division of Public Health (DPH) is increasing options available to persons to receive second doses as supply allows. These include more pharmacies, Primary Care Providers or vaccination events operated by Vault Health or Curative.
Learn about all the options on where you can be vaccinated: coronavirus.delaware.gov/vaccine/where-can-i-get-my-vaccine.
Should I Be Vaccinated?
Beebe Healthcare is offering the vaccine to all our team members because we see the evidence that the vaccine is safe and effective.
Everyone eligible for the vaccine should consider vaccination during this public health crisis. The more that are vaccinate the closer the country comes to herd immunity, which is when enough of the population is vaccinated and the virus cannot spread.
You should consult your physician before receiving the vaccine if you:
- have any allergies
- have a fever
- have a bleeding disorder or are on a blood thinner
- are immunocompromised or are on a medicine that affects your immune system
- are pregnant or plan to become pregnant
- are breastfeeding.
Additional resource for those who are pregnant or breastfeeding: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html
How Was the Vaccine Created & How Does it Work?
The Pfizer and Moderna COVID-19 vaccines, which have both received FDA approval and permission for emergency use, use a technology with messenger RNA (mRNA).
mRNA is the blueprint that our bodies usually use to create proteins. The protein created by these vaccines will in turn cause the body’s immune system to form antibodies (special proteins created by the body to fight off infection) against the COVID-19 virus.
It is natural to have apprehension to a new vaccine especially during these difficult times. The process to develop these vaccines have been tremendous and the speed at which we will now receive them is not due to a lack in safety. Learn more about the safety and technology of the vaccine.
Safety is a top priority and is considered before any vaccine before any vaccine is recommended for use. Learn more about how CDC and its partners are ensuring the safety of COVID-19 vaccines: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety.html.
What are the Side Effects?
Many want to understand the vaccines safety and effectiveness. The reports of higher than 90% efficacy is certainly a good sign.
Most common side effects are:
- Redness at the injection site
- Swelling or pain at the injection site
- Muscle pain
8 Things to Know about the U.S. COVID-19 Vaccination Program https://www.cdc.gov/coronavirus/2019-ncov/vaccines/8-things.html
#TeamBeebe On The COVID-19 Vaccine
Frequently Asked Questions
Please keep in mind that information changes rapidly. We strive to have the information below as updated as possible.
There is a five-step, rigorous process for drug and vaccine testing. The critical first step is three phases of clinical trials to learn how the vaccine works in humans. There are more than 100 clinical trials for a vaccine in the U.S., with five of them in the third (or largest and final) stage.
More than 70,000 volunteers were involved in Pfizer’s and Moderna’s stage-three trials. Results from both indicated that the vaccine candidate was well-tolerated and able to produce an immune response.
The vaccine was developed in a much shorter period of time due to the obvious need to address the public health threat the pandemic posed to the nation. The shorter development time is the result of technology advances to map the virus’s DNA and using vaccine platforms developed for other diseases.
The clinical trial process was accelerated by enrolling more people in trials to enhance rapid data collection and earlier analysis of safety data for demographically diverse populations. This also sped up the FDA review process as they have been monitoring the data all along.
Delivery/distribution time was shortened by allowing manufacturing to occur at the same time as instead of after, vaccine approval. A shorter review time does not mean the vaccine is unsafe. Experts and scientists from the FDA and the Advisory Committee on Immunization Practices reviewed the vaccine development data. Extensive post-monitoring efforts will be implemented to safeguard those immunized.
Recognizing the importance of testing within minority populations, vaccine developers worked with community engagement partners to enroll a diverse pool of participants. At least one manufacturer reported 37% of clinical trial volunteers were volunteers from racial and ethnic minority groups. The FDA and CDC will continue to monitor the safety of COVID-19 vaccines, to make sure even very rare side effects are identified. Another reported approximately 42% of global participants and 30% of U.S. participants in the Phase 3 study had racially and ethnically diverse backgrounds, and 41% of global and 45% of U.S. participants were 56-85 years of age.
DPH, with recommendations from the Delaware Public Health and Medical Ethics Advisory Group (Ethics Group) will review the CDC list of prioritized population groups and determine allocation and distribution of vaccine(s). The Ethics Group recommendations will be made based on which groups are most at risk due to how the virus is transmitted (close contact, indoor facilities), the severity rate of the virus in the community, and based on the population groups identified by the CDC. Persons of color work in many of the industries identified for Tier 1 and Tier 2 vaccination. Additionally, both Delaware’s COVID Vaccine Task Force and the Communications subcommittee, include representation from organizations representing communities of color and incorporate their feedback into planning.
The COVID-19 infection may pose serious risks to those who get the virus as well as those around the infected person. The virus also comes with potential for long-term health issues after recovery from COVID-19 disease. Because scientists are still learning more about the virus that causes COVID-19, it is not known whether getting COVID-19 disease will protect everyone against getting it again. Getting a COVID vaccine allows a person’s body to develop an immune response to a virus without getting sick from the virus itself.
According to the CDC, experts are still learning how a vaccine will provide protection under real-life conditions. We will still need to practice precautions such as wearing a face covering over your mouth and nose, social distancing (staying 6 feet away from others), and frequent handwashing.
It’s very important to continue protection protocols even after getting the vaccine. Medical experts feel very confident that the COVID-19 vaccine can protect you from the virus and help get us all back to normal — but not before a large number of people get the vaccine.
Getting the vaccine does not give you the all-clear to stop masking up and practicing social distancing. It is very important to continue to protect yourself and loved ones, and prevent the spread of COVID-19 — even after you get the vaccine — by continuing wearing a mask, practicing social distancing, washing your hands, and staying home if you’re sick.
When a vaccine becomes widely available, people will be able to get it from their primary care provider, local participating pharmacies, Federally Qualified Health Center, or from the Delaware Division of Public Health. All providers will complete required trainings with authorized vaccine coordinators. Satellite, temporary, or off-site settings may also be utilized to make the vaccine accessible. Enrolled medical providers may receive vaccinations either from the federal level directly or through DPH based on order size and storage needs.
The vaccine will be given to the American people at no cost. However, vaccination providers may be able to charge an office visit fee and will be able to charge an administration fee for giving the vaccine. Vaccine providers can be reimbursed for this fee.
Yes, you can get the vaccine if you have had COVID-19. Most people experience mild side effects from the vaccine. The vaccine itself will not give you COVID-19.
There is not enough information currently available to say if or for how long after infection someone is protected from getting COVID-19 again; this is called natural immunity. Early evidence suggests natural immunity from COVID-19 may not last very long, but more studies are needed to better understand this. In its recommendation to the CDC, Pfizer reported that the vaccination should be offered to persons regardless of history of prior symptomatic or asymptomatic SARS-CoV-2 (COVID-19) infection.
No. Information about the studies and the candidates can be found on the following website https://coronaviruspreventionnetwork.org/understanding-clinical-studies/ or by visiting the manufactures websites.
mRNA vaccines are a new type of vaccine to protect against infectious diseases. To trigger an immune response, many vaccines put a weakened or inactivated germ into our bodies. mRNA vaccines do not. Instead, they teach our cells how to make a protein that triggers an immune response inside our bodies. That immune response, which produces antibodies, is what protects us from getting infected if the real virus enters our bodies.
Specifically, COVID-19 mRNA vaccines give instructions for our cells to make a harmless piece of what is called the “spike protein.” The spike protein is found on the surface of the virus that causes COVID-19. Once a person receives the vaccine, the instructions (mRNA) are inside the muscle cells and the cells use them to make the protein piece. After the protein piece is made, the cell breaks down the instructions and gets rid of them. It does not alter or interact with your DNA in any way. Our immune systems recognize that the protein doesn’t belong there and begin building an immune response and making antibodies, like what happens in natural infection against COVID-19.
The benefit of mRNA vaccines, like all vaccines, is those vaccinated gain this protection without ever having to risk the serious consequences of getting sick with COVID-19.
It is still unknown at this time, how long that would take, but the more people who choose to get the vaccine, the greater chance of reaching herd immunity there will be.
With limited supply of vaccine from the federal government, it is hard to plan clinics several weeks in advance. As more vaccine becomes available, appointments for vaccine events through Vault Health, Curative, as well as pharmacies and medical offices will be easier to get. Please be patient as this may take weeks.
We are keeping a tally that of those who have received dose #1 at Beebe’s Millsboro Vaccine clinic. As vaccine becomes available and you are eligible for the second dose, we will be reaching out to you for the option to receive your second dose. There is a free text messaging reminder service to remind people to get their second dose. To enroll, text ENROLL to 1-833-VAXTEXT (829-8398).
The State of Delaware has released additional details for those awaiting a second dose:
If you received your first dose at the Dover DMV on January 16, 17 or 18 or Salesianum School on January 18, you will be invited to an event operated by Curative from Feb. 15-19 at Delaware Technical Community College (DTCC) campuses in Georgetown, Dover, and Wilmington.
Registration will be done directly with Curative and individuals will be required to show proof of their first dose vaccination date when they arrive on site.
The State of Delaware has requested that the Federal Emergency Management Agency (FEMA) stand up a vaccination site at Dover International Speedway for multiple days beginning as early as February 20. The FEMA site would be dedicated to vaccinating people who received their first dose at the Dover DMV January 16, 17 or 18; Salesianum School on January 18; at the Delaware City DMV January 22, 23 or 24; or at the Georgetown DMV January 23 or 24. Individuals will be required to show proof of their first dose vaccination date.
Lost vaccination card? Delawareans who have lost their vaccination card should email their full name and date of birth to firstname.lastname@example.org. For those without email access, call DPH at 1-833-643-1715.
While it is currently recommended that people receive a second dose as close to the recommended timeframe as possible (21 or 28 days), we are awaiting further federal guidance on if this window can be extended, and the manufacturers have not said that there is a date after that at which the vaccine series would need to be re-started.
• The CDC did recently announce that you may have a second dose up to 42 days from your first dose.
• The CDC also said if you do not receive your second dose within 42 days that you do not need to restart the series over again. You should not get the second dose earlier than the recommended interval.
The FDA approved emergency use of the vaccine developed by Johnson & Johnson and Janssen in late February. This vaccine was developed using the common cold instead of using mRNA like the other two approved vaccines - Pfizer and Moderna.
The Johnson & Johnson vaccine uses a common cold virus that has been engineered to make it harmless. It then safely carries part of the coronavirus's genetic code into the body. This is enough for the body to recognize the threat and then learn to fight coronavirus. This trains the body's immune system to fight coronavirus when it encounters the virus for real.
Additionally, this vaccine only requires one dose as compared to the two-dose Moderna and Pfizer versions.
The effectiveness of vaccines is tested during clinical trials and then reviewed by the FDA. Vaccines are approved by the FDA following clinical guidelines to determine safety. All vaccines must go through clinical trials.
The AstraZeneca vaccine will follow the same protocols. Once clinical trials are done, they will apply to the FDA. The FDA will review the data and then make a decision on whether it will be distributed under Emergency Use in the United States.